

Tiago A Mestre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5733218/publications.pdf>

Version: 2024-02-01

104
papers

2,593
citations

212478

28
h-index

263392

45
g-index

110
all docs

110
docs citations

110
times ranked

3633
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel. Canadian Journal of Neurological Sciences, 2022, 49, 19-28.	0.3	8
2	An <scp>MDS</scp> Evidence-Based Review on Treatments for Huntington's Disease. Movement Disorders, 2022, 37, 25-35.	2.2	19
3	Epidemiology and economic burden of Huntington's disease: a Canadian provincial public health system perspective. Journal of Medical Economics, 2022, 25, 212-219.	1.0	7
4	Co-designing a digital companion with people living with Parkinson's to support self-care in a personalized way: The eCARE-PD Study. Digital Health, 2022, 8, 205520762210816.	0.9	11
5	The Disease Modification Conundrum in Parkinson's Disease: Failures and Hopes. Frontiers in Aging Neuroscience, 2022, 14, 810860.	1.7	17
6	Evaluation of the Impact of Integrated Care and Self-Management After Deep Brain Stimulation in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1279-1284.	1.5	1
7	Disease Burden of Huntington's Disease (HD) on People Living with HD and Care Partners in Canada. Journal of Huntington's Disease, 2022, , 1-15.	0.9	1
8	Using Big Data in Movement Disorders: Disease States and Progression in Huntington's Disease. Movement Disorders, 2022, 37, 441-443.	2.2	0
9	Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. Movement Disorders, 2022, 37, 1304-1309.	2.2	11
10	Coping Styles in Patients with Parkinson's Disease: Consideration in the Co-Designing of Integrated Care Concepts. Journal of Personalized Medicine, 2022, 12, 921.	1.1	2
11	Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. Movement Disorders, 2022, 37, 1749-1755.	2.2	3
12	The Role of Parkinson Nurses for Personalizing Care in Parkinson's Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1807-1831.	1.5	3
13	Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease. Movement Disorders, 2021, 36, 398-406.	2.2	13
14	The Integrated Parkinson's disease Care Network (IPCN): Qualitative evaluation of a new approach to care for Parkinson's disease. Patient Education and Counseling, 2021, 104, 136-142.	1.0	7
15	Toward e-Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. Movement Disorders Clinical Practice, 2021, 8, 208-214.	0.8	5
16	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. Journal of Parkinson's Disease, 2021, 11, 395-404.	1.5	56
17	Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic. Parkinsonism and Related Disorders, 2021, 86, 97-100.	1.1	23
18	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. Movement Disorders, 2021, 36, 1964-1967.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Thyrotoxicosis Resulting in Unilateral Upper Limb Chorea and Ballismus. Canadian Journal of Neurological Sciences, 2021, , 1-2.	0.3	3
20	Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. Journal of Personalized Medicine, 2021, 11, 623.	1.1	18
21	Return on Investment Analysis for the Integrated Parkinson's Care Network: Lesson Learned from a Pilot Study. Journal of Parkinson's Disease, 2021, 11, 1-7.	1.5	0
22	F01's...Development of the huntington's disease integrated staging system (HD-ISS). , 2021, , .		1
23	Drooling rating scales in Parkinson's disease: A systematic review. Parkinsonism and Related Disorders, 2021, 91, 173-180.	1.1	12
24	Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme. Parkinsonism and Related Disorders, 2021, 93, 89-96.	1.1	3
25	Remote Evaluation of Parkinson's Disease Using a Conventional Webcam and Artificial Intelligence. Frontiers in Neurology, 2021, 12, 742654.	1.1	13
26	Are genetic and idiopathic forms of Parkinson's disease the same disease?. Journal of Neurochemistry, 2020, 152, 515-522.	2.1	28
27	Measurement Instruments to Assess Functional Mobility in Parkinson's Disease: A Systematic Review. Movement Disorders Clinical Practice, 2020, 7, 129-139.	0.8	28
28	Patient-centred management of Parkinson's disease. Lancet Neurology, The, 2020, 19, 887-888.	4.9	2
29	Moving towards home-based community-centred integrated care in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 78, 21-26.	1.1	27
30	Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial. Movement Disorders, 2020, 35, 2319-2323.	2.2	10
31	Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology. Frontiers in Neurology, 2020, 11, 575975.	1.1	32
32	Therapy of Parkinson's Disease Subtypes. Neurotherapeutics, 2020, 17, 1366-1377.	2.1	42
33	Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies. Neurotherapeutics, 2020, 17, 1645-1659.	2.1	40
34	The Role of Architecture and Design in the Management of Parkinson's Disease: A Systematic Review. Journal of Parkinson's Disease, 2020, 10, 1301-1314.	1.5	5
35	Huntington's Disease and Hypertension: Sorting Out Mixed Messages. Movement Disorders, 2020, 35, 915-917.	2.2	0
36	Nocebo and lessebo effects. International Review of Neurobiology, 2020, 153, 121-146.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Designing socially acceptable mHealth technologies for Parkinson's disease self-management. Finnish Journal of EHealth and EWelfare, 2020, 12, 163-178.	0.0	5
38	The dawn of a new era for neurodegenerative disorders: Huntington's disease leading the way. Movement Disorders, 2019, 34, 1301-1302.	2.2	3
39	Intermittent undulating tongue as an involuntary movement in early amyotrophic lateral sclerosis. Parkinsonism and Related Disorders, 2019, 67, 1-2.	1.1	1
40	Canadian guideline for Parkinson disease. Cmaj, 2019, 191, E989-E1004.	0.9	90
41	Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". Parkinsonism and Related Disorders, 2019, 66, 245-246.	1.1	0
42	Synuclein Meeting 2019: where we are and where we need to go. Journal of Neurochemistry, 2019, 150, 462-466.	2.1	3
43	Nocebo response in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2019, 65, 13-19.	1.1	18
44	MDS evidence-based review of treatments for essential tremor. Movement Disorders, 2019, 34, 950-958.	2.2	108
45	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. Movement Disorders, 2019, 34, 657-663.	2.2	213
46	The Parkinson's disease "diary": Developing a clinical and research tool for the digital age. Movement Disorders, 2019, 34, 676-681.	2.2	43
47	An 8-year-old boy with ataxia and abnormal movements. Paediatrics and Child Health, 2019, 24, 297-298.	0.3	0
48	Recent advances in the therapeutic development for Huntington disease. Parkinsonism and Related Disorders, 2019, 59, 125-130.	1.1	13
49	Development of the Integrated Parkinson™s Care Network (IPCN): using co-design to plan collaborative care for people with Parkinson™s disease. Quality of Life Research, 2019, 28, 1355-1364.	1.5	33
50	Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2018, 5, 361-372.	0.8	22
51	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. Movement Disorders, 2018, 33, 960-965.	2.2	12
52	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. Movement Disorders, 2018, 33, 742-749.	2.2	23
53	A rare cause of orofacial dyskinesias. Parkinsonism and Related Disorders, 2018, 50, 122-123.	1.1	1
54	Rating scales for cognition in Huntington's disease: Critique and recommendations. Movement Disorders, 2018, 33, 187-195.	2.2	38

#	ARTICLE	IF	CITATIONS
55	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 111-117.	0.8	27
56	Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2018, 15, 97.	2.4	71
57	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 503-510.	1.5	18
58	Introducing the new "Movement Disorders Rounds". <i>Parkinsonism and Related Disorders</i> , 2018, 55, 1.	1.1	0
59	Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?. <i>Movement Disorders</i> , 2018, 33, 1228-1235.	2.2	21
60	The placebo response in Parkinson's disease and other movement disorders. <i>Movement Disorders</i> , 2018, 33, 1193-1194.	2.2	2
61	Assessing and managing Parkinson's disease from home: A 21st century vision closer to reality. <i>Movement Disorders</i> , 2018, 33, 1407-1407.	2.2	0
62	Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. <i>Lancet Neurology</i> , The, 2018, 17, 842.	4.9	7
63	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.	1.1	63
64	Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 42-45.	1.1	22
65	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018, 33, 1195-1203.	2.2	3
66	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018, 8, 131-139.	1.5	10
67	Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 212-224.	0.8	137
68	Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 18.	2.0	19
69	Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations". <i>Movement Disorders</i> , 2017, 32, 482-482.	2.2	0
70	Impact of New Technologies in a Stroke Presentation: A Case of Dystextia and Dystypia. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 458-460.	0.3	5
71	Placebo and nocebo responses in restless legs syndrome. <i>Neurology</i> , 2017, 88, 2216-2224.	1.5	46
72	Are placebo pills presented as experimental treatment a true placebo?. <i>Pain</i> , 2017, 158, 535-535.	2.0	4

#	ARTICLE	IF	CITATIONS
73	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology</i> , The, 2017, 16, 28-29.	4.9	6
74	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. <i>Journal of Huntington's Disease</i> , 2017, 6, 157-163.	0.9	50
75	Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the EDIGT score. <i>European Journal of Neuroscience</i> , 2017, 45, 175-191.	1.2	17
76	PO104...Placebo and nocebo responses in rls: a meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A39.1-A39.	0.9	0
77	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309942.	0.9	100
78	Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. <i>Frontiers in Neurology</i> , 2016, 7, 27.	1.1	19
79	Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. <i>PLoS ONE</i> , 2016, 11, e0157852.	1.1	36
80	Transducer-based evaluation of tremor. <i>Movement Disorders</i> , 2016, 31, 1327-1336.	2.2	64
81	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	2.2	44
82	A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. <i>Neurogenetics</i> , 2016, 17, 245-249.	0.7	21
83	Motor and nonmotor heterogeneity of <i>LRRK2</i> -related and idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1192-1202.	2.2	102
84	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016, 31, 290-298.	2.2	68
85	Long-term double-blind unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1570-1574.	2.2	47
86	A12...How does Enroll-HD expedite/facilitate the conduct of clinical trials?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A4.1-A4.	0.9	0
87	I31...Enroll-HD: current status. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A69.2-A70.	0.9	0
88	I30...Enroll-HD: a global clinical research platform for huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A69.1-A69.	0.9	0
89	What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1349-1354.	1.1	24
90	Restless Genital Syndrome in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1559.	4.5	42

#	ARTICLE	IF	CITATIONS
91	Another face of placebo: The lessebo effect in Parkinson disease. <i>Neurology</i> , 2014, 82, 1402-1409.	1.5	45
92	Subthalamic nucleusâ€œdeep brain stimulation for early motor complications in Parkinson's diseaseâ€œthe EARLYSTIM trial: Early is not always better. <i>Movement Disorders</i> , 2014, 29, 1751-1756.	2.2	68
93	Current Use of Domperidone and Co-prescribing of Medications that Increase Its Arrhythmogenic Potential Among Older Adults: A Population-Based Cohort Study in Ontario, Canada. <i>Drugs and Aging</i> , 2014, 31, 805-813.	1.3	6
94	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 67-69.	0.8	14
95	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 915-918.	1.1	17
96	Reluctance to start medication for Parkinson's disease: A mutual misunderstanding by patients and physicians. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 608-612.	1.1	5
97	Diagnosis and treatment of impulse control disorders in patients with movement disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2013, 6, 175-188.	1.5	29
98	5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 411-421.	1.9	53
99	What motivates Parkinsonâ€™s disease patients to enter clinical trials?. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 667-671.	1.1	26
100	Therapeutic interventions for symptomatic treatment in Huntington's disease. <i>The Cochrane Library</i> , 2009, , CD006456.	1.5	91
101	Therapeutic interventions for disease progression in Huntington's disease. <i>The Cochrane Library</i> , 2009, , CD006455.	1.5	52
102	Therapeutic interventions for daytime somnolence in Parkinson's disease. <i>The Cochrane Library</i> , 2007, , .	1.5	0
103	Therapeutic interventions for sleep disorders in Parkinson's disease. <i>The Cochrane Library</i> , 0, , .	1.5	0
104	Emerging targets and other stimulationrelated procedures in the management of Parkinson's disease. , 0, , 216-230.		0